Redx Pharma (LSE:REDX) Gross-Profit-to-Asset % : 11.04% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Redx Pharma's annualized Gross Profit for the quarter that ended in Sep. 2023 was £3.78 Mil. Redx Pharma's average Total Assets over the quarter that ended in Sep. 2023 was £34.24 Mil. Therefore, Redx Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 11.04%.

Redx Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for Redx Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma Gross-Profit-to-Asset % Chart

Redx Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

27.55

26.57

27.69

36.64

9.54

Redx Pharma Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															36.91	42.04	40.37	8.78	11.04

Competitive Comparison of Redx Pharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Redx Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redx Pharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Redx Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Redx Pharma's Gross-Profit-to-Asset % falls into.

Redx Pharma Gross-Profit-to-Asset % Calculation

Redx Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Sep. 2023 )	/	( (Total Assets (A: Sep. 2022 )	+	Total Assets (A: Sep. 2023 ))	/ count )
	=	4.202	/	( (62.477	+	25.636)	/ 2 )
	=	4.202	/	44.0565
	=	9.54 %

Redx Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	3.782	/	( (42.848	+	25.636)	/ 2 )
	=	3.782	/	34.242
	=	11.04 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Redx Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Redx Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Redx Pharma (LSE:REDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.redxpharma.com

Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines